Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 24, 2017
What is the competitive landscape for ABBOTT, and what generic alternatives to ABBOTT drugs are available?
ABBOTT has one hundred and fourteen approved drugs.| Patents: | 6 |
| Tradenames: | 92 |
| Ingredients: | 65 |
| NDAs: | 114 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott | CEPHALOTHIN SODIUM | cephalothin sodium | INJECTABLE;INJECTION | 062548-001 | Sep 11, 1985 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Abbott | ERYTHROCIN | erythromycin lactobionate | INJECTABLE;INJECTION | 062586-001 | Jan 4, 1988 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Abbott | AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER | amino acids; dextrose | INJECTABLE;INJECTION | 019118-001 | Oct 11, 1984 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Abbott | A-METHAPRED | methylprednisolone sodium succinate | INJECTABLE;INJECTION | 089574-001 | Feb 22, 1991 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Abbott | AMINOSYN 3.5% M IN PLASTIC CONTAINER | amino acids; magnesium acetate; phosphoric acid; potassium acetate; sodium chloride | INJECTABLE;INJECTION | 018804-002 | May 15, 1984 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott | HYTRIN | terazosin hydrochloride | CAPSULE;ORAL | 020347-001 | Dec 14, 1994 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbott | HYTRIN | terazosin hydrochloride | TABLET;ORAL | 019057-001 | Aug 7, 1987 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbott | HYTRIN | terazosin hydrochloride | TABLET;ORAL | 019057-004 | Aug 7, 1987 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbott | PROSOM | estazolam | TABLET;ORAL | 019080-002 | Dec 26, 1990 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbott | HYTRIN | terazosin hydrochloride | CAPSULE;ORAL | 020347-001 | Dec 14, 1994 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
ritonavir | Capsules | 100 mg | NORVIR | 10/31/2012 |
ritonavir | Tablets | 100 mg | NORVIR | 12/21/2010 |
sibutramine hydrochloride | Capsules | 10 mg and 15 mg | MERIDIA | 8/14/2009 |
fenofibrate | Tablets | 48 mg | TRICOR | 7/1/2008 |
fenofibrate | Tablets | 145 mg | TRICOR | 10/19/2007 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,596,317 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | ► Subscribe | |||||||||||||||||||||||||||
| 8,343,540 | Process for producing fenofibrate tablets | ► Subscribe | |||||||||||||||||||||||||||
| 8,329,214 | Process for producing fenofibrate tablets | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turkey | 9901660 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 2513 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2263714 | ► Subscribe | |||||||||||||||||||||||||||
| Ukraine | 61096 | ► Subscribe | |||||||||||||||||||||||||||
| Estonia | 04042 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90020-1 | Sweden | ► Subscribe | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 | ||||||||||||||||||||||||||
| C/GB01/008 | United Kingdom | ► Subscribe | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 | ||||||||||||||||||||||||||
| C/GB01/053 | United Kingdom | ► Subscribe | PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; REGISTERED: DE 41531.00.00 19990114; DE 41531.01.00 19990114; DE 41533.00.00 19990114; DE 41533.01.00 19990114; CH IKS 54770 19990113; UK PL 0169/0129 20010511; UK PL 0169/0130 20010511 | ||||||||||||||||||||||||||
| C/GB11/045 | United Kingdom | ► Subscribe | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 | ||||||||||||||||||||||||||
| 00522 | Netherlands | ► Subscribe | PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,114 others who get our Drug Patent Expiration Alerts:
